はじめての方へ
ショーケース
価格
ログイン
無料体験
米国企業
UroGen Pharma Ltd.
UroGen Pharma Ltd.
URGN
時価総額
$4.1億
PER
マイリストに追加
マイリストに追加
サマリーテーブルに戻る
十億
百万
千
USD
年次
四半期
Download CSV
損益計算書
バランスシート
キャッシュフロー
2017年
12月31日
2018年
12月31日
2019年
12月31日
2020年
12月31日
2021年
12月31日
2022年
12月31日
Net loss
-20
-76
-105
-128
-111
-110
Depreciation and amortization
-
-
-
-
1
1
Inventory Obsolescence
-
-
-
-
-
1
Accrued financing on prepaid forward obligation
-
-
-
-
15
14
Amortization (accretion) on marketable securities
-
-
1
-0
-0
0
Share-based compensation
6
31
30
28
23
11
Amortization of discount on long-term debt
-
-
-
-
-
2
Amortization of right of use assets
-
-
-
-
1
1
Inventory
0
-0
-
2
3
0
Accounts receivable
-0
-
-
7
5
1
Prepaid expenses and other current assets
1
-0
0
2
4
4
Other non-current assets
-
-
-
-
1
1
Accounts payable and accrued expenses
3
4
3
-1
2
0
Employee related accrued expenses
1
3
2
3
-3
1
Other current liabilities
-
-
-
-
0
-1
Lease liabilities
-
-
-
-
-
-1
Uncertain tax positions
-
-
-
3
0
0
Net cash used in operating activities
-10
-37
-71
-106
-85
-88
Purchases of marketable securities
-
-
198
30
52
63
Sales of marketable securities
-
-
-
-
2
-
Maturities of marketable securities
-
-
-
-
54
64
Purchases of property and equipment
0
1
0
1
1
0
Net cash provided by investing activities
-36
35
-146
93
4
1
Proceeds from prepaid forward arrangement
-
-
-
-
72
-
Proceeds from exercise of options into ordinary shares
0
2
4
1
0
2
Proceeds from issuance of long-term debt
-
-
-
-
-
96
Issuance cost related to at-the-market issuances
-
-
0
0
0
0
Net cash provided by financing activities
62
66
165
17
72
97
Increase (Decrease) in Cash and Cash Equivalents
-
64
-51
4
-9
11
Non-cash issuance cost
-
-
-
-
0
-
Right of use assets obtained in exchange for new operating lease liabilities
-
-
2
-
-0
2